Inhibitor Therapeutics, Inc. filed its 10-K on Mar 30, 2022 for the period ending Dec 31, 2021. In this report its auditor, Cherry, Bekaert & Holland, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.089 USD | +0.03% | -35.32% | -3.26% |
03-29 | Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board | CI |
1st Jan change | Capi. | |
---|---|---|
-3.26% | 15.31M | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- INTI Stock
- News Inhibitor Therapeutics, Inc.
- Inhibitor Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt